Primary Chemotherapy in Stage IV Ovarian Cancer. A Prospective Phase II Study

Recchia, F.; Filippis, Sandro De; Rosselli, Michele; Saggio, Gaetano; Carta, G; Rea, Silvio

doi:10.1097/00006254-200202000-00016

Cited by 7 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…• ten references reported on non-comparable controlled trials or non-randomised studies (Kuhn 2001;Recchia 2001;Ikeba 2004;Angioli 2006;;Fuso 2006;Giannopoulos 2006;Lee 2006;Matulonis 2009;JCOG 2009);…”

Section: Description Of Studiesmentioning

confidence: 99%

Interval debulking surgery for advanced epithelial ovarian cancer

Tangjitgamol

Manusirivithaya

Laopaiboon

et al. 2016

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Section: Description Of Studiesmentioning

confidence: 99%

Interval debulking surgery for advanced epithelial ovarian cancer

Tangjitgamol

Manusirivithaya

Laopaiboon

et al. 2016

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

“…From several retrospective phase II studies, it appears that the outcome of these women, treated with neoadjuvant chemotherapy followed by interval debulking surgery, is essentially the same as for patients treated with primary debulking surgery followed by chemotherapy. These studies are summarized in Table 2 (21,36–59) . In most of these studies, interval debulking surgery was performed after three or four courses of neoadjuvant chemotherapy.…”

Section: Neoadjuvant Chemotherapy and Interval Debulking Surgerymentioning

confidence: 99%

“…Better survival for patients treated with NAC compared with nondebulked tumors Kuhn et al (46) 37 Better median survival in the group treated with NAC compared with primary debulked group Recchia et al (47) 34…”

Section: Neoadjuvant Chemotherapy Followed By Interval Debulking Surgmentioning

confidence: 99%

Timing of debulking surgery in advanced ovarian cancer

Vergote

Gorp

Amant

et al. 2008

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

It is clear that primary debulking remains the standard of care within the treatment of advanced ovarian cancer (FIGO stage III and IV). This debulking surgery should be performed by a gynecological oncologist without any residual tumor load, or so-called "optimal debulking." Over the last decades, interest in the use of neoadjuvant chemotherapy together with an interval debulking has increased. Neoadjuvant therapy can be used for patients who are primarily suboptimally debulked due to an extensive tumor load. In this situation, based on the randomized European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group trial, interval debulking by an experienced surgeon improves survival in some patients who did not undergo optimal primary debulking surgery. Based on the GOG 152 data, interval debulking surgery does not seem to be indicated in patients who underwent primarily a maximal surgical effort by a gynecological oncologist. Neoadjuvant chemotherapy can also be used as an alternative to primary debulking. In retrospective analyses, neoadjuvant chemotherapy followed by interval debulking surgery does not seem to worsen prognosis compared to primary debulking surgery followed by chemotherapy. However, we will have to wait for the results of future randomized trials to know whether neoadjuvant chemotherapy followed by interval debulking surgery is a good alternative to primary debulking surgery in stage IIIc and IV patients. Open laparoscopy is probably the most valuable tool for evaluating the operability primarily or at the time of interval debulking surgery.

show abstract

“…Chimiothérapie première + chirurgie d'intervalle versus cytoréduction d'emblée en cas de carcinose importante 8.4.1. Résultats de la sélection bibliographique Dans le cadre de la mise à jour 2007, les équations de recherche utilisées ont permis de selectioner 1 méta-analyse[36], 1 essai randomisé de phase III[37], 2 études prospectives comparatives[38,39], 1 étude prospective non comparative de phase II[40] et 3 études rétrospectives comparatives [41-43] indexés dans la base de données Medline ® entre le 1 er janvier 1997 et le 30 août 2007. 8.4.2.…”

unclassified

Standards, Options et Recommandations 2007 pour la prise en charge des patientes atteintes de tumeurs epitheliales malignes de lovaire - Traitement chirurgical, mise a jour 2007 (rapport abrege)

2008

Gynécologie Obstétrique & Fertilité

View full text Add to dashboard Cite

Primary Chemotherapy in Stage IV Ovarian Cancer. A Prospective Phase II Study

Cited by 7 publications

References 0 publications

Interval debulking surgery for advanced epithelial ovarian cancer

Interval debulking surgery for advanced epithelial ovarian cancer

Timing of debulking surgery in advanced ovarian cancer

Standards, Options et Recommandations 2007 pour la prise en charge des patientes atteintes de tumeurs epitheliales malignes de lovaire - Traitement chirurgical, mise a jour 2007 (rapport abrege)

Contact Info

Product

Resources

About